Retatrutide

A research medicine that acts on GIP, GLP-1 and glucagon receptors.

Sources for this tile

• Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)
• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

The review includes the earlier obesity study and a published 2026 diabetes phase 3 trial. The two groups had different conditions.

Sources for this tile

• Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)
• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Open the pathway notes below. A biological pathway is a possible chain of events in the body. The grade states where it was tested.

Sources for this tile

• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Each proposed mechanism

Three signal receivers

The medicine combines three hormone receptor actions. Trial outcomes are still specific to the group studied.

Evidence note: Described biology; not directly tested by this outcome trial

Sources

• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Go deeper

Three signal receivers Described biology; not directly tested by this outcome trial

The medicine combines three hormone receptor actions. Trial outcomes are still specific to the group studied.

Sources

• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Open the outcome notes. They show the tested condition and what was measured. A positive marker, a mouse result and a clinical benefit are different things.

Sources for this tile

• Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)
• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Read this before you read a benefit into it

Laboratory and animal results describe what happened in that model. They are not proven healing in a person. Human studies name their own population, outcome and limits. Both are kept apart here on purpose.

Human research found for this product

Retatrutide: obesity phase 2 A

Proof grade	A
Design	Randomised placebo-controlled phase 2
People or model	Adults with obesity or overweight plus a weight-related condition
Number	338
Outcome measured	Weight
Result	Mean change at 48 weeks ranged from -8.7% to -24.2% across active groups, versus -2.1% with placebo.
Route in the study	Subcutaneous
Duration	48 weeks
Risks noted	Gut symptoms and dose-related heart rate increases.
Personal regimen	Not set. A study regimen is not a personal instruction.

Source

• Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)

TRANSCEND-T2D-1: retatrutide phase 3 A

Proof grade	A
Design	Randomised placebo-controlled phase 3
People or model	Adults with type 2 diabetes inadequately controlled by diet and exercise
Number	537
Outcome measured	HbA1c and weight
Result	At 40 weeks, mean HbA1c fell by 1.69, 1.86 and 1.94 percentage points in active groups, versus 0.81 with placebo. Mean weight fell 11.5%, 13.9% and 15.3%, versus 2.6%.
Route in the study	Subcutaneous
Duration	40 weeks
Risks noted	Mostly gut symptoms; 2-5% stopped for adverse events.
Personal regimen	Not set. A study regimen is not a personal instruction.

Source

• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Go deeper

Weight A

A: Tested in Adults with obesity or overweight plus a weight-related condition. Read the study result in the human or researcher layer. This is a tested outcome, not a promised benefit.

Sources

• Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)

HbA1c and weight A

A: Tested in Adults with type 2 diabetes inadequately controlled by diet and exercise. Read the study result in the human or researcher layer. This is a tested outcome, not a promised benefit.

Sources

• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Each claim keeps its own source, evidence grade and limits. This is a scoped first research edition. It is not a full review or a personal treatment plan.

Sources for this tile

• Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)
• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Overall state of the evidence

Status: scoped-human-evidence

Do not call this a general repair or anti-ageing product. Current local approval and the exact supplier formulation are not verified.

Risk summary

Do not call this a general repair or anti-ageing product. Current local approval and the exact supplier formulation are not verified.

Unwanted effects reported in the sources

• Gut symptoms and dose-related heart rate increases. (Retatrutide: obesity phase 2)
• Mostly gut symptoms; 2-5% stopped for adverse events. (TRANSCEND-T2D-1: retatrutide phase 3)

What is still open

• Supplier identity and batch match have not been verified
• Full-text systematic review and complete interactions are not finished
• Diabetes medicines
• Gut and heart rate history
• Exact formulation and current regulatory record

Checks a reviewer must finish first

• Diabetes medicines
• Gut and heart rate history
• Exact formulation and current regulatory record

How to read the proof grades

• A: Controlled human trial. Note whether randomisation and blinding were confirmed.
• B: Small uncontrolled human study or chart review.
• C: Whole-animal intervention.
• D: Cell or other laboratory study.
• E: User reports. Kept separate and never substituted for a measured outcome.
• ungraded: Identity sources, official labels, notices, reviews and unverified claims are not assigned an efficacy grade.

Go deeper

How to read the proof Open the checked detail

A: controlled human trial. State whether it was blinded and randomized. B: small uncontrolled human study or chart review; a weak clinical comparison is marked with its design limits. C: whole-animal work. D: cells or other lab work. E: user reports.

A grade describes the kind of evidence for one claim. It does not grade every claim about a peptide or approve a product. Labels, history and regulatory reviews are named sources, not efficacy grades.

Sources

• Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)

Open questions Open the checked detail

Supplier identity and batch match have not been verified

Full-text systematic review and complete interactions are not finished

Diabetes medicines

Gut and heart rate history

Exact formulation and current regulatory record

Open the linked human study records. Each names the tested group, design, result and limits. Related-compound and non-treatment studies are marked so they cannot be used as product treatment proof.

Sources for this tile

• Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)
• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Studies named in this tile

Personal regimen	Not set. A study regimen is not a personal instruction.

Personal regimen	Not set. A study regimen is not a personal instruction.

What people report

No user reports are recorded for this product. The library keeps human studies and user reports in separate places, so nothing is filled in here.

Each human record

Retatrutide: obesity phase 2 A

Proof grade	A
Design	Randomised placebo-controlled phase 2
People or model	Adults with obesity or overweight plus a weight-related condition
Number	338
Outcome measured	Weight
Result	Mean change at 48 weeks ranged from -8.7% to -24.2% across active groups, versus -2.1% with placebo.
Route in the study	Subcutaneous
Duration	48 weeks
Risks noted	Gut symptoms and dose-related heart rate increases.
Personal regimen	Not set. A study regimen is not a personal instruction.

Source

• Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)

TRANSCEND-T2D-1: retatrutide phase 3 A

Proof grade	A
Design	Randomised placebo-controlled phase 3
People or model	Adults with type 2 diabetes inadequately controlled by diet and exercise
Number	537
Outcome measured	HbA1c and weight
Result	At 40 weeks, mean HbA1c fell by 1.69, 1.86 and 1.94 percentage points in active groups, versus 0.81 with placebo. Mean weight fell 11.5%, 13.9% and 15.3%, versus 2.6%.
Route in the study	Subcutaneous
Duration	40 weeks
Risks noted	Mostly gut symptoms; 2-5% stopped for adverse events.
Personal regimen	Not set. A study regimen is not a personal instruction.

Source

• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

This is the shared library. No client has been assessed in this record. This tile will use the person's own words, a named target and checked rule-outs after intake. A catalog entry does not mean it is suitable for someone.

Do not call this a general repair or anti-ageing product. Current local approval and the exact supplier formulation are not verified.

Sources for this tile

• Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)
• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Weekly injections under the skin were tested. No client dose or escalation plan is filled. Research routes describe what was studied. They are not a client administration guide.

Sources for this tile

• Retatrutide: obesity phase 2 (Jastreboff and colleagues · 2023 · Published abstract · checked 2026-10-08)
• TRANSCEND-T2D-1: retatrutide phase 3 (Bajaj and colleagues · 2026 · Published abstract · checked 2026-10-08)

Routes seen in the research

• Subcutaneous

Dose and cycle fields in the library

These are blank on purpose. A personal amount, schedule, mixing or storage instruction is only written into an agreed plan after a reviewer checks the exact product.